Discoveries in Health Policy

Ideas for or from an evolving healthcare system

Monday, November 16, 2026

CMS Publishes Template for Uses of SUPER INTELLIGENCE in Medicare, Medicaid

›
Recall that recently, HHS ordered that HHS, CMS, NIH, FDA, all use "SUPER INTELLIGENCE" rather than artificial intelligence.  My b...

FDA Downclassifies Again: IHC for CDx

›
I posted a blog on September 3, 2026, that FDA had recently downclassified oncology cDx with ISH or FISH from  Class III (PMA) to Class II ...

Using AI at my Desk at Work: A Weekly Agentic Search for AI Report Generation Advances (Radiology or Pathology)

›
 Each Monday, I used "agentic AI" to run a complex scheduled AI search in Chat GPT.  The topic is new publications related to gene...
Thursday, November 12, 2026

Two Authors, Two Books on Digital Pathology

›
 This week, I ran across two authors on Linked In who have each written a book that introduces the world of digital pathology. The first aut...

Brief Blog: How CMS Updates Products Covered Under NCDs

›
A brief update on how CMS covers products that are covered by definition, under an NCD.   The example here is NCD 90.2, Uses of NGS in Cance...
Wednesday, November 11, 2026

PAMA: The Secret Data Views that CMS Never Displays (for GSP Genomic Sequencing Procedures)

›
Medicare genomic sequencing pricing under PAMA is based on anywhere from 200 to 275,000 claims for the "GSP" service type.   For E...
Tuesday, November 10, 2026

Devil in the Details; Understanding GeneDx's Earning Shocks via Reimbursement

›
  GeneDx Earnings Calls Show Why Reimbursement Determines the Economics of Genomic Testing GeneDx’s May earnings shock (down 50%) exposed t...
Sunday, November 8, 2026

Chris Klomp: #2 at HHS, Update on his Views and Priorities for CMS

›
HEADER.  Chris Klomp is about to become the official #2 at HHS - the Deputy Secretary.  How does Klomp think Medicare should pay for innova...
Saturday, November 7, 2026

AI Guest Faculty: Lessons from 1870s for Growth of Genomics Today

›
 What can the rise of Germany’s synthetic-dye industry in the 1800s teach us about American genomics today? Johann Peter Murmann’s fascinati...
Friday, November 6, 2026

Three Companies: Investor Calls for Tempus AI, Caris, and Natera, Quarter to Quarter

›
Tempus, Caris, and Natera see enormous opportunity in genomics—but reimbursement determines the pace. Our new AI-generated white paper comp...

Why a Strong Diagnostic Test May Add Little New Information

›
 # Why a Strong Diagnostic Test May Add Little "New" Information [Chat GPT 6] My colleague Luis Cano recently posted a useful exam...
Thursday, November 5, 2026

The Genomics Consulting Book Guide to CLAUDE

›
If this looks familiar, I posted at Linked In   about November 1, but not here at the DIHP blog. They Infest Linked In Lately, every day Lin...
Wednesday, November 4, 2026

CMS Pulls Algorithmic Lab Tests Off the CLFS: The CY2027 SaMS Rules, Decoded

›
  CMS Pulls Algorithmic Lab Tests Off the CLFS: The CY2027 SaMS Rules, Decoded Wednesday, November 4, 2026 AI CORNER [ New replacement ar...

Why Some Genomics Labs Reach Financial "Escape Velocity" - But Many Don't

›
Recently, Merck KGaA annnounced it was acquiring BioTechne for over $11 billion dollars.  BioTechne's management has been strong - that...
Tuesday, November 3, 2026

Puzzling PAMA Pricing #2: Labs & Losses Deep Dive

›
 You've heard about how PAMA affects different groups - big labs, small labs, physician labs, and the labs of different medical specialt...
›
Home
View web version

About the Author

My photo
Bruce
Bruce Quinn MD PhD is an expert on health reform, innovation, and Medicare policy. He helps both large and small companies understand and overcome hurdles to commercialization, as well as craft business strategies for a changing environment. CONTACT Dr. Quinn through www.brucequinn.com. BACKGROUND: Dr. Quinn has worked in academic medicine, Accenture business strategies, and for the Medicare program. EDUCATION: Stanford MD/PhD, MIT Postdoc, Kellogg MBA.
View my complete profile
Powered by Blogger.